Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Organon & Co. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Organon Reports Results for the Second Quarter Ended June 30, 2023",
"Second Quarter 2023 Earnings Organon"
07/07/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "AMENDMENT NO. 1"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/07/2023 SC 13G/A BlackRock Inc. reports a 6.4% stake in Organon & Co.
12/09/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "AMENDED AND RESTATED BYLAWS of Organon & Co. Article I CORPORATE OFFICES Section 1.1          Registered Office . The registered office of Organon & Co. shall be fixed in the Certificate of Incorporation of the Corporation . Section 1.2          Other Offices . The Corporation may also have an office or offices, and keep the books and records of the Corporation, except as otherwise required by law, at such other place or places, either within or without the State of Delaware, as the Board of Directors may designate or as the business of the Corporation may from time to time require. Article II MEETINGS OF STOCKHOLDERS Section 2.1       &#8239..."
11/03/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Organon & Co. Moderator: Ali, Kevin 08:30 AM ET"
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/21/2022 10-K Annual Report for the period ended December 31, 2021
02/17/2022 8-K Investor presentation, Quarterly results
Docs: "Organon reports results for the fourth quarter and full year ended December 31, 2021",
"Company Information Presentation"
02/10/2022 SC 13G/A VANGUARD GROUP INC reports a 11.4% stake in Organon & Co.
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/12/2021 8-K Quarterly results
Docs: "Organon reports results for the third quarter ended September 30, 2021",
"Organon & Co. Moderator: Ali, Kevin 08:30 AM ET",
"Q3 2021 Earnings Organon"
08/16/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/12/2021 8-K Quarterly results
07/12/2021 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/29/2021 8-K Quarterly results
06/21/2021 10-Q Quarterly Report for the period ended March 31, 2021
06/03/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/03/2021 8-K Resignation/termination of a director
Docs: "FORM 8-K",
"Separation and Distribution Agreement, by and between Merck & Co., Inc. and Organon & Co",
"Amended and Restated Certificate of Incorporation of Organon & Co",
"Amended and Restated Bylaws of Organon & Co",
"Tax Matters Agreement, by and between Merck & Co., Inc. and Organon & Co",
"Employee Matters Agreement, by and between Merck & Co., Inc. and Organon & Co",
"Transition Services Agreement, by and between Merck & Co., Inc. and Organon & Co",
"Transition Services Agreement, by and between Merck & Co., Inc. and Organon & Co",
"Indenture, among Organon Finance 1 LLC, Organon Foreign Debt Co-Issuer B.V., U.S. Bank National Association, as trustee and collateral agent, and Elavon Financial Services DAC, UK Branch, as principal paying agent, transfer agent and registrar, with respect to 2.875% Senior Secured Notes due 2028",
"Indenture, among Organon Finance 1 LLC, Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee and collateral agent, with respect to 4.125% Senior Secured Notes due 2028",
"Indenture, among Organon Finance 1 LLC, Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee, with respect to 5.125% Senior Notes due 2031"
05/07/2021 SEC STAFF ACTION Form SEC STAFF ACTION - SEC Staff Action: ORDER
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy